The Checkmate 141 and Keynote 040 trials demonstrated increased OS in platinum-refractory R/M HNSCC, using nivolumab and pembrolizumab, respectively, although in the Keynote 040 the benefit was limited to patients with PD-L1-positive disease (6, 7). Here, CD274 is linked to head and neck squamous cell carcinoma.